{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:23Z","timestamp":1792268663085,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100159"],"award-info":[{"award-number":["82100159"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of intolerance. This phase 2 trial investigated the safety and efficacy of jaktinib, a novel JAK inhibitor in patients with ruxolitinib\u2010intolerant MF. The primary endpoint was the proportion of patients with \u226535% reduction in spleen volume (SVR35) at week 24. The secondary endpoints included change of MF\u2010related symptoms, anemic response, and safety profiles. Between December 18, 2019, and November 24, 2021, 51 patients were enrolled, 45 treated with jaktinib 100\u2009mg bid (100\u2009mg bid group) and six received non\u2010100\u2009mg bid doses (non\u2010100\u2009mg bid group). The SVR35 at week 24 in the 100\u2009mg bid group was 43.2% (19\/44, 95% CI 29.7%\u201357.8%). There were 41.9% (13\/31) of transfusion\u2010independent patients with hemoglobin (HGB) \u2264100\u2009g\/L who had HGB elevation \u226520\u2009g\/L within 24\u2009weeks. The proportion of patients with a \u226550% decrease in the total symptom score (TSS 50) at week 24 was 61.8% (21\/34). The most commonly reported grade \u22653 treatment\u2010emergent adverse events (TEAEs) in the 100\u2009mg bid group were anemia 31.1%, thrombocytopenia 22.2%, and infectious pneumonia 17.8%. A total of 16 (35.6%) in the 100\u2009mg bid group had serious adverse events, and 4 (8.9%) were considered possibly drug related. These results indicate jaktinib can provide a treatment option for patients with MF who are intolerant to ruxolitinib.<\/jats:p>","DOI":"10.1002\/ajh.27033","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T12:05:55Z","timestamp":1689854755000},"page":"1588-1597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single\u2010arm, open\u2010label, phase 2, multicenter study"],"prefix":"10.1002","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-2288","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou People's Republic of China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang People's Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological disorders  Hangzhou People's Republic of China"},{"name":"Zhejiang University Cancer Center  Hangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital  Zhengzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-6300","authenticated-orcid":false,"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College Peking Union Medical College Hospital  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of Jilin University  Changchun People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-5897","authenticated-orcid":false,"given":"Guangsheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize  Jiangsu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University Third Hospital  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ruijin Hospital Shanghai Jiaotong University Medical School  Shanghai People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangming","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital The Third Hospital of Shanxi Medical University  Taiyuan People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-3828","authenticated-orcid":false,"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital Sichuan University  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunkang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology Shanghai Jiao Tong University Affiliated Sixth People's Hospital  Shanghai People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences  Guangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-0112","authenticated-orcid":false,"given":"Mei","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Third Xiangya Hospital Central South University  Changsha People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of Hebei Medical University  Shijiazhuang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Hospital of Qingdao University  Qingdao People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital Southern Medical University  Guangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology  Luoyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhua","family":"Lu","sequence":"additional","affiliation":[{"name":"Suzhou Zelgen Biopharmaceuticals Co, Ltd  Suzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewen","family":"Yin","sequence":"additional","affiliation":[{"name":"Suzhou Zelgen Biopharmaceuticals Co, Ltd  Suzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Suzhou Zelgen Biopharmaceuticals Co, Ltd  Suzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Suo","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou People's Republic of China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang People's Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological disorders  Hangzhou People's Republic of China"},{"name":"Zhejiang University Cancer Center  Hangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical pharmacy the First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-7385","authenticated-orcid":false,"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College  Tianjin People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou People's Republic of China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou Zhejiang People's Republic of China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological disorders  Hangzhou People's Republic of China"},{"name":"Zhejiang University Cancer Center  Hangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"issue":"2","key":"e_1_2_11_3_1","first-page":"121","article-title":"Myelofibrosis: clinicopathologic features, prognosis, and management","volume":"16","author":"O'Sullivan JM","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33541"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282612"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00780-9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00596-z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26709"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26714"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"issue":"1","key":"e_1_2_11_28_1","article-title":"Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate\u2010 or high\u2010risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial","volume":"138","author":"Gupta V","year":"2021","journal-title":"Blood"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147614"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1048"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163456"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"issue":"10","key":"e_1_2_11_33_1","first-page":"858","article-title":"Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1\u2010year follow\u2010up of A2202","volume":"37","author":"Jin J","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26778"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T18:13:38Z","timestamp":1694110418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/ajh.27033"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27033","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"2023-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}